94,230 results match your criteria Estrogen Therapy


Breast Reduction Following Hormonal Therapy in a Transgender Female Patient.

Ann Plast Surg 2019 Apr 22. Epub 2019 Apr 22.

From the Division of Plastic and Reconstructive Surgery, Icahn School of Medicine at Mount Sinai, New York, NY.

In male-to-female gender transition, individuals request a number of interventions, including hormonal therapy, to promote feminizing characteristics. Estrogen-based medication is prescribed to increase breast development, decrease facial hair, promote feminine adipose tissue deposition, and soften skin. Surgical breast augmentation to supplement unsatisfying breast growth after hormonal therapy is a common and well-studied course of management for such transgender patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SAP.0000000000001855DOI Listing

Effects of Hormone Therapy on List and Story Recall in Post-Menopausal Women.

Exp Aging Res 2019 Apr 25:1-24. Epub 2019 Apr 25.

b Department of Public Health Sciences, School of Medicine , University of California , Davis , USA.

Background/Study Context: A number of longitudinal randomized controlled trials (LRCT) have used free verbal recall tests to study the effects of post-menopausal estrogen hormone therapy (HT) on episodic memory, but none have explicitly explored contrasts between list and story recall, in spite of cognitive differences between the tasks. For example, list recall provides little support for the use of gist, while story recall emphasizes it, and there is evidence that estrogen produces gist bias. Moreover, we present a literature tabulation that also suggests a task-specific HT effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0361073X.2019.1609169DOI Listing

The efficacy of Ankaferd Blood Stopper in an experimental Asherman syndrome model created in rats.

Turk J Obstet Gynecol 2019 Mar 27;16(1):7-14. Epub 2019 Mar 27.

Çanakkale Onsekiz Mart University Faculty of Medicine, Department of Gynecology and Obstetrics, Çanakkale, Turkey.

Objective: Asherman syndrome (AS) is a progressive disease involving menstrual disorders, recurrent pregnancy losses, and infertility developing as a result of partial or full blockade of the uterine cavity with adhesions. AS generally develops after trauma to the basal layer of the endometrium. In spite of a variety of methods such as adhesiolysis, inserting intrauterine devices, and administering high doses of estrogen, treatments remain insufficient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4274/tjod.galenos.2018.21298DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463422PMC

No vaginal estrogen therapy arm in an RCT trial on genitourinary syndrome of menopause is a concern.

Climacteric 2019 Apr 24. Epub 2019 Apr 24.

b Department of Gynecology , Wesley Hospital , Brisbane , Australia.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13697137.2019.1
Publisher Site
http://dx.doi.org/10.1080/13697137.2019.1597842DOI Listing
April 2019
1 Read

Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers.

NPJ Breast Cancer 2019 18;5:15. Epub 2019 Apr 18.

Nashville Breast Center, Nashville, TN USA.

Immunohistochemically ER-positive HER2-negative (ER+HER2-) breast cancers are classified clinically as Luminal-type. We showed previously that molecular subtyping using the 80-gene signature (80-GS) reclassified a subset of ER+HER2- tumors to molecular Basal-type. We report here that molecular reclassification is associated with expression of dominant-negative ER variants and evaluate response to neoadjuvant therapy and outcome in the prospective neoadjuvant NBRST study (NCT01479101). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-019-0109-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472385PMC

[Summary and expectation of the role of GnRHa in the treatment of breast cancer].

Authors:
X L Li Y Yu X Y Zong

Zhonghua Zhong Liu Za Zhi 2019 Apr;41(4):246-250

Department of Breast Surgery, Shanghai Jiao Tong University affiliated Shanghai Sixth People's Hospital, Shanghai 200233, China.

Gonadotropin-releasing-hormone analogues (GnRHa) are widely used in the treatment of premenopausal breast cancer. The anti-tumor effect of GnRHa is similar to that of surgical castration or chemotherapy, through reversibly inhibiting ovarian function and downregulating the estrogen level in premenopausal female. At the same time, GnRHa can protect the ovarian function, avoiding premature ovarian failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-3766.2019.04.002DOI Listing

Automated Quantification of Extranuclear ERα using Phosphor-integrated Dots for Predicting Endocrine Therapy Resistance in HR/HER2 Breast Cancer.

Cancers (Basel) 2019 Apr 12;11(4). Epub 2019 Apr 12.

Department of Medical Physics, Graduate School of Medicine, Tohoku University, Sendai, Miyagi 980-8574, Japan.

In addition to genomic signaling, Estrogen receptor alpha (ERα) is associated with cell proliferation and survival through extranuclear signaling contributing to endocrine therapy (ET) resistance. However, the relationship between extranuclear ERα and ET resistance has not been extensively studied. We sought to measure extranuclear ERα expression by immunohistochemistry using phosphor-integrated dots (IHC-PIDs) and to assess its predictive value for ET resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11040526DOI Listing

Secretory Carcinoma of the Breast: Clinicopathologic Profile of 14 Cases Emphasizing Distant Metastatic Potential.

Histopathology 2019 Apr 23. Epub 2019 Apr 23.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Aims: Secretory carcinoma of the breast (SCB) is a rare histologic type of breast carcinoma with a generally indolent clinical behavior. We aim to elucidate the clinical, pathological and molecular findings of SCB cases and identify characteristics associated with aggressive clinical courses.

Methods And Results: Fourteen patients with SCB were identified, including 12 women and 2 men, with a median age of 56 years (range, 8-81 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13879DOI Listing

The effect of breast volume on toxicity using hypofractionated regimens for early stage breast cancer for patients.

Adv Radiat Oncol 2019 Apr-Jun;4(2):261-267. Epub 2018 Nov 1.

Department of Radiation Oncology, University of Kansas Cancer Center, Kansas City, Kansas.

Purpose: Hypofractionated radiation therapy (HFRT) remains underused, despite multiple randomized trials showing the equivalence of HFRT to conventional fractionated radiation therapy (CFRT). We sought to retrospectively review the relationship between breast volume and toxicity for HFRT versus CFRT.

Methods And Materials: Data from 114 patients who received a diagnosis of early stage breast cancer and were treated with lumpectomy and whole breast radiation alone were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2018.10.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460101PMC
November 2018

High Expression of Pseudogene PTTG3P Indicates a Poor Prognosis in Human Breast Cancer.

Mol Ther Oncolytics 2019 Sep 27;14:15-26. Epub 2019 Mar 27.

Program of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.

Pseudogenes play pivotal roles in tumorigenesis. Previous studies have suggested that pituitary tumor-transforming 3, pseudogene (PTTG3P), serves as an oncogene in human cancers. However, its expression pattern, biological function and underlying mechanism in breast cancer remain unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.omto.2019.03.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463746PMC
September 2019
1 Read

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients.

J Bone Oncol 2019 Jun 4;16:100237. Epub 2019 Apr 4.

Division of Endocrinology, Diabetes and Bone Diseases, Department of Medicine III, TU Dresden Medical Center, Fetscherstraße 74, D-01307 Dresden, Germany.

Background: Semaphorin 4D (Sema4D) is a glycoprotein that inhibits bone formation and has been associated with cancer progression and the occurrence of bone metastases. Recently, Sema4D expression has been linked to estrogen signaling in breast cancer. Endocrine therapies like tamoxifen and aromatase inhibitors (AI) are a standard therapeutic approach in hormone receptor positive breast cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbo.2019.100237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461588PMC

A novel orally active inverse agonist of estrogen-related receptor gamma (ERRγ), DN200434, a booster of NIS in anaplastic thyroid cancer.

Clin Cancer Res 2019 Apr 22. Epub 2019 Apr 22.

Laboratory Animal Center, Daegu-Gyeongbuk Medical Innovation Foundation

Purpose: New strategies to restore sodium iodide symporter (NIS) expression and function in radioiodine therapy-refractive anaplastic thyroid cancers (ATCs) are urgently required. Recently, we reported the regulatory role of estrogen-related receptor gamma (ERRγ) in ATC cell NIS function. Herein, we identified DN200434 as a highly potent (functional IC = 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3007DOI Listing

Longitudinal impact of the Women's Health Initiative study on hormone therapy use in Australia.

Climacteric 2019 Apr 23:1-9. Epub 2019 Apr 23.

a School of Pharmacy , University of Queensland , Woolloongabba , QLD , Australia.

Purpose: This study aimed to examine the longitudinal impact of evidence changes on menopausal hormone therapy (MHT) use in Australia.

Methods: We analyzed two datasets of subsidized and total MHT use (2000-2016) using segmented regression analysis to explore the impact of the Women's Health Initiative (WHI) 2002 and 2007 studies. Analyses were stratified by class, route, and strength. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13697137.2019.1593357DOI Listing
April 2019
1 Read

HIGH expression of OSM and IL-6 are associated with decreased breast cancer survival: synergistic induction of IL-6 secretion by OSM and IL-1β.

Oncotarget 2019 Mar 12;10(21):2068-2085. Epub 2019 Mar 12.

Boise State University, Biomolecular Sciences Program, Boise, ID, USA.

Chronic inflammation has been recognized as a risk factor for the development and maintenance of malignant disease. Cytokines such as interleukin-6 (IL-6), oncostatin M (OSM), and interleukin-1 beta (IL-1β) promote the development of both acute and chronic inflammation while promoting metrics of breast cancer metastasis. However, anti-IL-6 and anti-IL-1β therapeutics have not yielded significant results against solid tumors in clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26699DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459341PMC

TRPC3 Regulates the Proliferation and Apoptosis Resistance of Triple Negative Breast Cancer Cells through the TRPC3/RASA4/MAPK Pathway.

Cancers (Basel) 2019 Apr 18;11(4). Epub 2019 Apr 18.

School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China.

Currently, there is no effective molecular-based therapy for triple-negative breast cancer (TNBC). Canonical transient receptor potential isoform 3 (TRPC3) was previously shown to be upregulated in breast cancer biopsy tissues when compared to normal breast tissues. However, the biological role of TRPC3 in breast cancer still remains to be elucidated. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/2072-6694/11/4/558
Publisher Site
http://dx.doi.org/10.3390/cancers11040558DOI Listing
April 2019
1 Read

Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer.

Semin Cancer Biol 2019 Apr 16. Epub 2019 Apr 16.

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. Electronic address:

The possibility that a receptor for androgen is expressed in Breast Cancer (BC) is fascinating given that the tumor is predominantly estrogen-dependent. The androgen receptor (AR) is emerging as a new marker and a potential new therapeutic target in the treatment of BC patients. The recent availability of selective AR inhibitors (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2019.04.002DOI Listing
April 2019
7 Reads

Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.

FASEB J 2019 Apr 19:fj201802347RRR. Epub 2019 Apr 19.

Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Aromatase inhibitors are the preferred treatment for certain women with estrogen receptor (ER)-positive breast cancer, but evidence suggests that women with obesity experience aromatase inhibitor resistance at higher rates. To compare how stromal cells derived from women who are lean or obese influence response to the aromatase inhibitor (anastrazole), we incorporated patient-derived stroma in a previously characterized MCF7-derived duct model. Coculture with adipose stromal cells enabled the metabolism of testosterone (T) to E, which induced estrogen response element activity, epithelial proliferation, and hyperplasia in MCF7 cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.201802347RRRDOI Listing

Menopausal Hot Flashes: A Concise Review.

J Midlife Health 2019 Jan-Mar;10(1):6-13

Department of Obstetrics and Gynecology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Hot flashes (HFs), defined as transient sensations of heat, sweating, flushing, anxiety, and chills lasting for 1-5 min, constitute one of the most common symptoms of menopause among women though only a few seek treatment for these. The basis of HFs lies in abnormal hypothalamic thermoregulatory control resulting in abnormal vasodilatory response to minor elevations of core body temperature. Recent data suggest an important role for calcitonin gene-related peptide, hypothalamic kisspeptin, neurokinin B and dynorphin signal system, serotonin, norepinephrine in causation of HFs in addition to estrogen deficiency which plays a cardinal role. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jmh.JMH_7_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459071PMC

Regulation of estrogen signaling and breast cancer proliferation by an ubiquitin ligase TRIM56.

Oncogenesis 2019 Apr 18;8(5):30. Epub 2019 Apr 18.

Henan Key Laboratory of Immunology and Targeted Therapy, School of Laboratory Medicine, Henan Collaborative Innovation Center of Molecular Diagnosis and Laboratory Medicine, Xinxiang Medical University, 453003, Xinxiang, Henan, P.R. China.

Breast cancer ranks no. 1 in women cancer worldwide, while 60-70% are estrogen receptor alpha positive. The estrogen selective modulators, such as tamoxifen, become the effective drugs for controlling ER alpha breast cancer progression. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41389-019-0139-x
Publisher Site
http://dx.doi.org/10.1038/s41389-019-0139-xDOI Listing
April 2019
1 Read

Differential expression of senescence tumour markers and its implications on survival outcomes of breast cancer patients.

PLoS One 2019 18;14(4):e0214604. Epub 2019 Apr 18.

Ingham Institute for Applied Medical Research, Liverpool, NSW Australia.

Breast cancer is a heterogeneous disease displaying different histopathological characteristics, molecular profiling and clinical behavior. This study describes the expression patterns of senescence markers P53, DEC1 and DCR2 and assesses their significance on patient survival as a single or combined marker with P16 or P14 using breast cancer progression series. One thousand and eighty (1080) patients with primary invasive ductal carcinoma, no special type, were recruited through an 11-year retrospective study period. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214604PLOS
April 2019
2 Reads

Higher ER load is not associated with better outcome in stage 1-3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer.

Breast Cancer Res Treat 2019 Apr 17. Epub 2019 Apr 17.

Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.

Purpose: In breast cancer, hormone receptor (HR) status is generally a qualitative measure; positive or negative. Quantitatively measured oestrogen and progesterone receptors (ER and PR) are frequently proposed prognostic and predictive markers, some guidelines even provide different treatment options for patients with strong versus weak expression.

Aim: To evaluate quantitative HR load assessed by immunohistochemistry as a prognostic and predictive measure in stage 1-3 breast cancer. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-019-05233-9
Publisher Site
http://dx.doi.org/10.1007/s10549-019-05233-9DOI Listing
April 2019
3 Reads

Estrogen-deficient skin: The role of topical therapy.

Int J Womens Dermatol 2019 Jun 15;5(2):85-90. Epub 2019 Mar 15.

Montefiore Medical Center, Department of Medicine, Division of Dermatology, Bronx, New York.

Menopause is a major turning point in a woman's life that is characterized by declining ovarian function and decreased serum estrogen levels. The resulting hormonal changes particularly affect the skin, with postmenopausal symptoms such as loss of structural architecture and increased propensity to damage becoming rapidly noticeable. Interestingly, studies have shown that estrogen deprivation in postmenopausal conditions accelerates many skin changes, including dryness, atrophy, fine wrinkling, and poor wound healing. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23526475193000
Publisher Site
http://dx.doi.org/10.1016/j.ijwd.2019.01.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451761PMC
June 2019
5 Reads

LLGL2 rescues nutrient stress by promoting leucine uptake in ER breast cancer.

Nature 2019 Apr 17. Epub 2019 Apr 17.

Department of Medicine, Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Drosophila Lgl and its mammalian homologues, LLGL1 and LLGL2, are scaffolding proteins that regulate the establishment of apical-basal polarity in epithelial cells. Whereas Lgl functions as a tumour suppressor in Drosophila, the roles of mammalian LLGL1 and LLGL2 in cancer are unclear. The majority (about 75%) of breast cancers express oestrogen receptors (ERs), and patients with these tumours receive endocrine treatment. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41586-019-1126-2
Publisher Site
http://dx.doi.org/10.1038/s41586-019-1126-2DOI Listing
April 2019
4 Reads

Relationship between sex steroids and deterioration of bone microarchitecture in older men: the prospective STRAMBO Study.

J Bone Miner Res 2019 Apr 17. Epub 2019 Apr 17.

INSERM UMR 1033, University of Lyon, Hôpital Edouard Herriot, Lyon, France.

In older men, low estrogen levels are associated with poor bone microarchitecture. Data on androgens are discordant. We studied the link between baseline sex steroid levels (total 17β -estradiol [17βE2], total testosterone [tT], calculated bioavailable 17βE2 [bio-17βE2] and apparent free testosterone concentration [AFTC]) and bone microarchitecture deterioration assessed prospectively in a 820 older men followed up for 8 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbmr.3746DOI Listing

Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy.

NPJ Breast Cancer 2019 10;5:13. Epub 2019 Apr 10.

1Department of Radiation Biology, Institute for Cancer Research, Radium Hospital, Oslo University Hospital, Montebello, 0379 Oslo, Norway.

Currently the greatest challenge in oncology is the lack of homogeneity of the lesions where different cell components respond differently to treatment. There is growing consensus that monotherapies are insufficient to eradicate the disease and there is an unmet need for more potent combinatorial treatments. We have previously shown that hypericin photodynamic therapy (HYP-PDT) triggers electron transport chain (ETC) inhibition in cell mitochondria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41523-019-0108-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458138PMC
April 2019
1 Read

Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.

Sci Rep 2019 Apr 16;9(1):6124. Epub 2019 Apr 16.

Department of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.

Glioblastoma (GBM) is the most commonly diagnosed brain tumor that exhibit high mortality rate and chemotherapy resistance is a major clinical problem. Recent studies suggest that estrogen receptor beta (ERβ), may function as a tumor suppressor in GBM. However, the mechanism(s) by which ERβ contributes to GBM suppression and chemotherapy response remains unknown. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-019-42313-8
Publisher Site
http://dx.doi.org/10.1038/s41598-019-42313-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467924PMC
April 2019
2 Reads

A Case of Locally Advanced Breast Cancer in a 59-Year-Old Man Requiring a Modified Approach to Management.

Am J Case Rep 2019 Apr 17;20:531-536. Epub 2019 Apr 17.

Department of General Surgery, Surgical Oncology Unit, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

BACKGROUND Male breast cancer is rare, accounting for approximately 1% of all malignancies in men. The lack of awareness of this rare cancer results in delayed diagnosis and its aggressive behavior can result in poor prognosis. This report is of a case of locally advanced, high-grade breast cancer in a 59-year-old man who was reluctant to undergo diagnostic procedures, and describes the approach to clinical management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12659/AJCR.915377DOI Listing
April 2019
1 Read

Estrogen-Dependent Functional Spine Dynamics in Neocortical Pyramidal Neurons of the Mouse.

J Neurosci 2019 Apr 16. Epub 2019 Apr 16.

The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, 916 Hunterian Building, 725 N. Wolfe Street, Baltimore, MD, 21205, USA

Surgical ovariectomy has been shown to reduce spine density in hippocampal CA1 pyramidal cells of rodents, and this reduction is reversed by 17β-estradiol (E2) treatment in a model of human estrogen replacement therapy. Here, we report reduction of spine density in apical dendrites of layer 5 pyramidal neurons of several neocortical regions that is reversed by subsequent E2 treatment in ovariectomized (OVX) female Thy1M-EGFP mice. We also found that OVX-associated reduction of spine density in somatosensory cortex was accompanied by a reduction in mEPSC frequency (but not mIPSC frequency), indicating a change in functional synapses. Read More

View Article

Download full-text PDF

Source
http://www.jneurosci.org/lookup/doi/10.1523/JNEUROSCI.2772-1
Publisher Site
http://dx.doi.org/10.1523/JNEUROSCI.2772-18.2019DOI Listing
April 2019
2 Reads

The effects of adjuvant endocrine therapy on bone health in women with breast cancer.

J Endocrinol 2019 Apr 1. Epub 2019 Apr 1.

M Grossmann, Medicine, University of Melbourne, Heidelberg, 3084, Australia.

In women with oestrogen-receptor (ER) positive early breast cancer, oestradiol is important for breast cancer development and progression. Endocrine therapy prevents the deleterious effects of oestradiol in breast tissue by systemically depleting oestradiol concentration (aromatase inhibitors) or preventing its local action in breast tissue (selective oestrogen receptor modulators i.e. Read More

View Article

Download full-text PDF

Source
https://joe.bioscientifica.com/view/journals/joe/aop/joe-19-
Publisher Site
http://dx.doi.org/10.1530/JOE-19-0077DOI Listing
April 2019
2 Reads

TP53 Status as a Determinant of Pro- versus Anti-tumorigenic Effects of Estrogen Receptor-beta in Breast Cancer.

J Natl Cancer Inst 2019 Apr 16. Epub 2019 Apr 16.

Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY.

Background: Anti-tumorigenic versus pro-tumorigenic roles of estrogen receptor-beta (ESR2) in breast cancer (BC) remain unsettled. We investigated the potential of TP53 status to be a determinant of the bi-faceted role of ESR2 and associated therapeutic implications for triple negative BC (TNBC).

Methods: ESR2-TP53 interaction was analyzed with multiple assays including in situ proximity ligation assay (PLA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djz051DOI Listing
April 2019
3 Reads

Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).

J Med Chem 2019 Feb 18;62(3):1420-1442. Epub 2019 Jan 18.

The estrogen receptor (ER) is a validated target for the treatment of estrogen receptor-positive (ER+) breast cancer. Here, we describe the design, synthesis, and extensive structure-activity relationship (SAR) studies of small-molecule ERα degraders based on the proteolysis targeting chimeras (PROTAC) concept. Our efforts have resulted in the discovery of highly potent and effective PROTAC ER degraders, as exemplified by ERD-308 (32). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.8b01572DOI Listing
February 2019

Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.

Gynecol Oncol 2019 Apr 13. Epub 2019 Apr 13.

Duke University Medical Center, Durham, NC, United States of America.

Objective: Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malignancies. In breast cancer, activating mutations in the estrogen receptor (mutESR1) contribute to therapeutic resistance to endocrine therapy, especially aromatase inhibitors (AIs). The purpose of this study was to evaluate the frequency and clinical relevance of ESR1 genomic alterations in gynecologic malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.04.010DOI Listing
April 2019
1 Read

A cmap-enabled gene expression signature-matching approach identifies small-molecule inducers of accelerated cell senescence.

BMC Genomics 2019 Apr 15;20(1):290. Epub 2019 Apr 15.

Department of Molecular Genetics and Cell Biology and Ludwig Center for Metastasis Research, The University of Chicago, 929 East 57th Street, GCIS W522A, Chicago, IL, 60637, USA.

Background: Diverse stresses including genotoxic therapy can induce proliferating cancer cells to undergo cellular senescence and take on the characteristic phenotypes of replicative cellular aging. This accelerated or therapy-induced senescence has been alternatively proposed to contribute to therapeutic efficacy or resistance. Toward better understanding this cell state, we sought to define the core transcriptome of accelerated senescence in cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12864-019-5653-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466706PMC

Cardiac arrhythmias secondary to hormone therapy in trans women.

Expert Rev Cardiovasc Ther 2019 Apr 15. Epub 2019 Apr 15.

b Division of Cardiology, Kingston Health Science Center , Queen's University , Kingston , Ontario , Canada.

Introduction: With greater social acceptance and the evolution of transgender medicine as a specialty, more trans women are seeking hormone therapy (HT). Several studies have identified an increase in cardiovascular disease in trans women, however no studies have investigated the incidence of arrhythmias. Using two cases from the authors' clinic as examples, we propose that hormone therapy in trans women may increase the risk of cardiac arrhythmias. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14779072.2019.1
Publisher Site
http://dx.doi.org/10.1080/14779072.2019.1606713DOI Listing
April 2019
2 Reads

Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance.

Cancers (Basel) 2019 Apr 4;11(4). Epub 2019 Apr 4.

Department of Food Science and Human Nutrition, University of Illinois, Urbana-Champaign, Urbana, IL 61801, USA.

A majority of breast cancer specific deaths in women with ERα (+) tumors occur due to metastases that are resistant to endocrine therapy. There is a critical need for novel therapeutic approaches to resensitize recurrent ERα (+) tumors to endocrine therapies. The objective of this study was to elucidate mechanisms of improved effectiveness of combined targeting of ERα and the nuclear transport protein XPO1 in overcoming endocrine resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11040479DOI Listing

Future Aspects for Cannabinoids in Breast Cancer Therapy.

Int J Mol Sci 2019 Apr 3;20(7). Epub 2019 Apr 3.

Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.

Cannabinoids (CBs) from provide relief for tumor-associated symptoms (including nausea, anorexia, and neuropathic pain) in the palliative treatment of cancer patients. Additionally, they may decelerate tumor progression in breast cancer patients. Indeed, the psychoactive delta-9-tetrahydrocannabinol (THC), non-psychoactive cannabidiol (CBD) and other CBs inhibited disease progression in breast cancer models. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/1422-0067/20/7/1673
Publisher Site
http://dx.doi.org/10.3390/ijms20071673DOI Listing
April 2019
1 Read

The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.

Am J Clin Pathol 2019 Apr 15. Epub 2019 Apr 15.

Breast Pathology Section, Department of Pathology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL.

Objectives: The aims were to evaluate the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) axis in ductal carcinoma in situ (DCIS) of the breast.

Methods: We reviewed 85 pure DCIS cases treated with surgical excision at our institution, including 51 luminal A (estrogen receptor [ER] positive/human epidermal growth factor 2 [HER2] negative), 15 luminal B (ER+/HER2+), 13 HER2 (ER-/HER2+), and six basal-like (ER-/HER2-/CK5/6+). The extent and intensity of PD-1 and PD-L1 immunohistochemical staining in the tumor-infiltrating lymphocytes (TILs) and in the tumor cells were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajcp/aqz020DOI Listing
April 2019
1 Read

The Case for an Estrogen-iron Axis in Health and Disease.

Exp Clin Endocrinol Diabetes 2019 Apr 12. Epub 2019 Apr 12.

Sharjah Institute for Medical Research, University of Sharjah, United Arab Emirates.

Clinical and experimental evidence suggest that estrogen manipulates intracellular iron metabolism and that elevated levels of estrogen associate with increased systemic iron availability. This has been attributed to the ability of estrogen to suppress hepcidin synthesis, maintain ferroportin integrity and enhance iron release from iron-absorbing duodenal enterocytes and iron-storing macrophages and hepatocytes. These observations speak of a potential "estrogen-iron" axis that manipulates iron metabolism in response to hematologic (erythropoiesis) and non-hematologic (uterine growth, pregnancy, lactation) needs for iron. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0885-1677DOI Listing
April 2019
1 Read

Estrogen receptor-α regulates the expression of syndecan-1 in human breast carcinoma cells.

Endocr Relat Cancer 2019 Apr 1. Epub 2019 Apr 1.

J Levallet, Laboratoire Oestrogène et Reproduction, Université de Caen Normandie, Caen, France.

Breast cancer (BC) is the primary cause of cancer-related mortality among women. Patients who express the estrogen receptor (ER), which mediates the tumorigenic effects of estrogens, respond to antihormonal therapy. Loss of ER expression or acquired resistance to E2 is associated with aggressive malignant phenotypes, which lead to relapse. Read More

View Article

Download full-text PDF

Source
https://erc.bioscientifica.com/view/journals/erc/aop/erc-18-
Publisher Site
http://dx.doi.org/10.1530/ERC-18-0285DOI Listing
April 2019
3 Reads

Development of a simple and rapid method for the detection of isomiroestrol in Pueraria candollei by an immunochromatographic strip test.

J Nat Med 2019 Apr 11. Epub 2019 Apr 11.

Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, 40002, Thailand.

Pueraria candollei (P. candollei) is a traditional Thai herb widely used for estrogen replacement therapy because it contains many unique chromenes that possess potent estrogenic activity, one of which is known as isomiroestrol. Since isomiroestrol is a promising compound that is solely present in P. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11418-019-01307-6
Publisher Site
http://dx.doi.org/10.1007/s11418-019-01307-6DOI Listing
April 2019
3 Reads

Small molecules for fat combustion: targeting obesity.

Acta Pharm Sin B 2019 Mar 19;9(2):220-236. Epub 2018 Sep 19.

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa 999078, Macau, China.

Obesity is increasing in an alarming rate worldwide, which causes higher risks of some diseases, such as type 2 diabetes, cardiovascular diseases, and cancer. Current therapeutic approaches, either pancreatic lipase inhibitors or appetite suppressors, are generally of limited effectiveness. Brown adipose tissue (BAT) and beige cells dissipate fatty acids as heat to maintain body temperature, termed non-shivering thermogenesis; the activity and mass of BAT and beige cells are negatively correlated with overweight and obesity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.apsb.2018.09.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438825PMC
March 2019
2 Reads

Development of novel and safer anti-breast cancer agents, SS1020 and SS5020, based on a fundamental carcinogenic research.

Genes Environ 2019 28;41. Epub 2019 Mar 28.

2Department of Pharmacological Sciences, State University of New York at Stony Brook, Stony Brook, 11794-8651 New York USA.

Tamoxifen (TAM) has been prescribed worldwide to patients with and women at high-risk of breast cancer. However, long-term use of TAM increases the incidence of endometrial cancer. The carcinogenic mechanisms of TAM have been extensively investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s41021-019-0124-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437986PMC
March 2019
1 Read

FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.

BMC Cancer 2019 Apr 11;19(1):351. Epub 2019 Apr 11.

School of Pharmacy, Queen's University Belfast, Belfast, UK.

Background: Optimising breast cancer treatment remains a challenge. Resistance to therapy is a major problem in both ER- and ER+ breast cancer. Tumour recurrence after chemotherapy and/or targeted therapy leads to more aggressive tumours with enhanced metastatic ability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5500-0DOI Listing

Tumor budding in infiltrating breast carcinoma: Correlation with known clinicopathological parameters and hormone receptor status.

Indian J Pathol Microbiol 2019 Apr-Jun;62(2):222-225

Department of Surgery, Maulana Azad Medical College, New Delhi, India.

Introduction: Tumor budding (TB) is proposed as an essential step in the invasion and metastasis of various tumors. However, there is limited information about its role in breast cancer. This study was designed to assess the prognostic significance of TB in clinical practice. Read More

View Article

Download full-text PDF

Source
http://www.ijpmonline.org/text.asp?2019/62/2/222/255800
Publisher Site
http://dx.doi.org/10.4103/IJPM.IJPM_120_18DOI Listing
April 2019
2 Reads

Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha.

PLoS One 2019 10;14(4):e0215340. Epub 2019 Apr 10.

Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, United Kingdom.

Estrogen Receptor alpha (ERα) plays a major role in most breast cancers, and it is the target of endocrine therapies used in the clinic as standard of care for women with breast cancer expressing this receptor. The two methods ChIP-seq (chromatin immunoprecipitation coupled with deep sequencing) and RIME (Rapid Immunoprecipitation of Endogenous Proteins) have greatly improved our understanding of ERα function during breast cancer progression and in response to anti-estrogens. A critical component of both ChIP-seq and RIME protocols is the antibody that is used against the bait protein. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215340PLOS
April 2019
4 Reads

Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer.

Pharmacogenomics J 2019 Apr 10. Epub 2019 Apr 10.

Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology IRCCS, Milan, Italy.

Polymorphisms of genes involved in estrogen synthesis have been linked to breast cancer risk, prognosis, and treatment response. We investigated the prognostic impact of a deletion spanning the entire UGT2B17 gene (UGT2B17*2) and genetic variants of the aromatase CYP19A1 and estrogen receptor α (ESR1) in 125 postmenopausal women with ER-positive breast cancer enrolled in a randomized pre-surgical trial. The UGT2B17*2 was estimated by copy number variation assays and the CYP19A1 rs10046/rs4646 and ESR1 rs2077647/rs2234693/rs9340799 by TaqMan allelic discrimination assays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41397-019-0087-zDOI Listing
April 2019
1 Read

Vitamin D treatment differentially affects anxiety-like behavior in the old ovariectomized female rats and old ovariectomized female rats treated with low dose of 17β-estradiol.

Authors:
Julia O Fedotova

BMC Med Genet 2019 Apr 9;20(Suppl 1):49. Epub 2019 Apr 9.

ITMO University, Saint-Petersburg, Russia.

Background: Estrogen deficiency effects on affective-related behavior are restricted to certain periods of age after ovary removal. Among other nutraceuticals, one of such «natural» substances for treatment of affective-related diseases could be vitamin D. It is a great interest to evaluate the effects of repeated cholecalciferol administration on anxiety-related behavior in the old female rats with long-term estrogen deficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12881-019-0774-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454671PMC
April 2019
1 Read

A case of pustular psoriasis possibly precipitated by estrogen/gestagen periodic therapy for Turner syndrome.

Clin Exp Dermatol 2019 Apr 8. Epub 2019 Apr 8.

Department of Dermatology, Osaka City General Hospital, Osaka.

Patients with Turner syndrome have an X chromosome abnormality in that they have only one X chromosome or show partial deletion of the X chromosome or mosaicism with an abnormal X chromosome. To compensate for the ovary dysfunction and restore bone density, estrogen/gestagen periodic therapy (Kaufmann therapy) is essential for patients with Turner syndrome. This article is protected by copyright. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.13979DOI Listing
April 2019
1 Read

De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.

Cancer Chemother Pharmacol 2019 Apr 8. Epub 2019 Apr 8.

Department of Breast and Endocrine Surgery, Osaka Medical College Hospital, 2-7 Daigaku-machi, Takatsuki-shi, Osaka, 569-8686, Japan.

Purpose: Neoadjuvant trastuzumab combined with anthracycline and taxane is now considered a standard regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. A less toxic, non-anthracycline regimen has been considered as a treatment option for patients with node-negative small tumors. Estrogen receptor-negative and HER2-positive (pure HER2) tumors are more likely to achieve a pathological complete response (pCR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03836-zDOI Listing
April 2019
1 Read